Archive
A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo
A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo Researchers at The Hospital for Sick Children (SickKids) have developed a novel antibody platform that enhances the targeting abilities of antibodies to combat SARS-CoV-2 variants. Leveraging the Multabody platform, co-developed by SickKids Senior Scientist Dr. Jean-Philippe Julien, these antibodies indicate increased potency, affording greater protection against SARS-CoV-2 viral variants. Promising lab results also show these antibodies indicate increased breadth, providing new neutralization effects against a broad spectrum of SARS viruses. This research establishes the Multabody platform as [...]
Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships
Radiant Biotherapeutics Emerges from Stealth Mode with $8 Million Seed Round and Two Pharma Partnerships Radiant Biotherapeutics, a revolutionary antibody platform company developing multi-valent, multi-specific therapeutics emerged from stealth mode unveiling an $8 million seed financing and two significant pharmaceutical partnerships. The Company, based on foundational IP from the labs of Dr. Jean-Philippe Julien at The Hospital for Sick Children (SickKids) and Dr. Bebhinn Treanor at the University of Toronto, was created by Amplitude Ventures which also led the seed round along with launch partner, SickKids and additional investors Alexandria Investments, [...]
Novel machine-learning algorithm creates atlas of cancer with potential as universal diagnostic platform
Novel machine-learning algorithm creates atlas of cancer with potential as universal diagnostic platform In the first broad comparison of paediatric and adult cancer, researchers at The Hospital for Sick Children (SickKids) have analyzed 13,000 individual cancers and built an ‘atlas’ of paediatric cancer using a novel machine-learning algorithm. The diagnosis of cancer is, for an estimated 18.1 million people worldwide per year, mostly reliant on the microscopic examination and detection of specific proteins. The accuracy of these methods is variable, and improvements are not easily shared between institutes. This is especially [...]
Researchers develop novel algorithm to unlock role of cellular phenomenon in aggressive cancers
Researchers develop novel algorithm to unlock role of cellular phenomenon in aggressive cancers Scientists at The Hospital for Sick Children (SickKids) have developed a novel computational tool to directly measure hypertranscription in tumour cells, a feature present in almost all cases of human cancer, with novel implications for treatment strategies. In the study published in Science Advances, researchers developed a new algorithm called RNAmp to examine over 7,000 tumours spanning 31 cancer types and demonstrated hypertranscription is present across most cancers. Hypertranscription is a unique phenomenon that occurs when transcription, the process [...]
Seventh annual SickKids gap funding competition advances health-care innovations
Seventh annual SickKids gap funding competition advances health-care innovations From potential treatments for Clostridium difficile infection and medulloblastoma to a new way to standardize pain behaviour tests, this year’s Proof of Principle (PoP) Grant Competition showcased innovative research advancements at The Hospital for Sick Children (SickKids). Hosted by SickKids Industry Partnerships & Commercialization (IP&C), the PoP Grant Competition is a pitch competition that provides funding to advance research discoveries and inventions with the objective of commercialization. Each of the awarded teams receive one year of funding to support their project and will collaborate with IP&C [...]
SickKids immunotargeting technology licensed exclusively to Providence Therapeutics
SickKids immunotargeting technology licensed exclusively to Providence Therapeutics The Hospital for Sick Children (SickKids), through the SickKids Industry Partnerships & Commercialization Office, has entered into an exclusive licensing agreement with Providence Therapeutics for an immunotargeting technology platform. This platform provides an approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells (APC's) of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to antigens which are coupled to the targeting monoclonal antibody (mAb). The innovation builds on pioneering work done by [...]
Innovation Showcase returns to highlight SickKids technologies and innovators
Innovation Showcase returns to highlight SickKids technologies and innovators Summary: Annual commercialization event offers attendees access to emerging therapeutic and diagnostic SickKids technologies with high potential for market disruption and clinical impact. The SickKids Innovation Showcase is returning for its second year, bringing together the latest in cutting-edge innovation at The Hospital for Sick Children (SickKids) with investors who can help advance ideas with the potential to improve health outcomes for patients. Hosted by the Industry Partnerships & Commercialization office at SickKids, the SickKids Innovation Showcase celebrates some of the most advanced health and life [...]
Whole-genome detection and interpretation of repeat expansions in autism and related disorders
Whole-genome detection and interpretation of repeat expansions in autism and related disorders Ryan Yuen, PhD Scientist | Genetics & Genome Biology Technology 1-Pager Lab Website Advancements in genome analysis have greatly improved gene discovery and clinical diagnosis for many human diseases, with genome sequencing becoming the current standard. While genome-sequencing data has enabled the identification of all classes of genetic variation, there are still difficulties in resolving genetic changes in more complex disorders, such as autism spectrum disorder (ASD). Despite over 100 genetic factors identified [...]
Machine learning-driven NGS-based diagnostic tests to optimize clinical response in oncology
Machine learning-driven NGS-based diagnostic tests to optimize clinical response in oncology Adam Shlien, PhD Associate Director | Translation Genetics Department of Paediatric Laboratory Medicine Uri Tabori, MD Staff Physician | Haematology/Oncology Senior Scientist | Genetics & Genome Biology Technology 1-Pager Dr. Shlien Full Bio Dr. Tabori Full Bio Dr. Roman Melnyk has brought his industry experience from Merck & Co. to his role as a Senior Scientist at SickKids. The Melnyk lab has developed a delivery platform that can transport various cargo [...]
MATCH: Machine learning algorithms for toxicity and cardiac health | Jason Maynes, PhD/MD
MATCH: Machine learning algorithms for toxicity and cardiac health Jason Maynes, PhD/MD Senior Scientist | Molecular Medicine Technology 1-Pager Lab Website Current drug discovery and animal models of cardiac function do not accurately predict cardiac activity or toxicity, resulting in the failure of 30% of drug candidates in development, market removal of 16% of approved drugs, and as a result, the loss of billions of drug development dollars. To identify cardiotoxic compounds earlier in the drug discovery continuum, Dr. Jason Maynes, the Director of Research [...]
Highly sensitive diagnostic tests for the prevention of sudden cardiac death | Robert Hamilton, MD
Highly sensitive diagnostic tests for the prevention of sudden cardiac death Robert Hamilton, MD Staff Cardiologist Senior Scientist | Translational Medicine Technology 1-Pager Full Bio Sudden Cardiac Death (SCD) causes more years of potential life lost than any other non-cancer disorder. The diagnosis of some SCD disorders, including Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) and Brugada Syndrome (BrS), is difficult and expensive using current clinical assessments, and after complete workup 2/3 of ARVC patients still go undiagnosed. Dr. Robert Hamilton, a clinician scientist at SickKids, led [...]
Engineered human alveolar-like macrophages as a cell therapy for respiratory diseases | Martin Post, PhD
Engineered human alveolar-like macrophages as a cell therapy for respiratory diseases Martin Post, PhD Senior Scientist | Translational Medicine Technology 1-Pager Lab Website Currently, there are inadequate therapeutic options for major respiratory diseases caused by prolonged inflammation leading to tissue damage and infection. Regenerative medicine for lung diseases has largely focused on the lung tissue lining, but the lung immune system has often been overlooked in approaches to disease treatment. The most abundant cell population in the lung airways are the alveolar macrophages (AM), which [...]
Methods of treating trinucleotide repeat expansion diseases | Christopher Pearson, PhD
Methods of treating trinucleotide repeat expansion diseases Christopher Pearson, PhD Senior Scientist | Genetics & Genome Biology Technology 1-Pager Full Bio Dr. Christopher Pearson is a Senior Scientist at SickKids with over 25 years of research in molecular genetics. The Pearson lab works on rare conditions that are caused by unnatural slips and loops in the DNA, such as Huntington’s disease, ALS, and 40+ other neurodegenerative diseases. In affected patients, these loops expand in size as the patient ages and eventually this results in the [...]
A novel cell-penetrant delivery platform applied to a pan-Ras targeting anti-cancer therapy | Roman Melnyk, PhD
A novel cell-penetrant delivery platform applied to a pan-Ras targeting anti-cancer therapy Roman Melnyk, PhD Senior Scientist | Molecular Medicine Technology 1-Pager Lab Website Dr. Roman Melnyk has brought his industry experience from Merck & Co. to his role as a Senior Scientist at SickKids. The Melnyk lab has developed a delivery platform that can transport various cargo into cells for diverse applications, including proteins of therapeutic significance as well as the CRISPR/Cas9 gene editing machinery. Ras is a class of GTPase proteins that plays [...]
Novel therapeutic compositions for degrading bacterial and fungal biofilms | P. Lynne Howell, PhD
Novel therapeutic compositions for degrading bacterial and fungal biofilms P. Lynne Howell, PhD Senior Scientist | Molecular Medicine Technology 1-Pager Lab Website Bacteria and fungal colonies produce a protective coating barrier called a biofilm, which makes it difficult for traditional antibiotics to penetrate the organisms. Dr. Lynne Howell is a Senior Scientist in the Molecular Medicine program at SickKids, and her team is focused on understanding how these biofilms are formed. In collaboration with the Sheppard lab at McGill University, they discovered a group of [...]
SickKids Ranked One of Canada’s Top 40 Research Hospitals for 2021
SickKids Ranked One of Canada's Top 40 Research Hospitals for 2021 SickKids has once again been named one of Canada’s top research hospitals by Research Infosource. SickKids ranks first in both researcher intensity and hospital intensity among medium-sized hospitals on the list. For the eleventh consecutive year, SickKids holds a top spot on the Top 40 Research Hospitals list, ranked as Canada’s number-two research hospital for 2021. Read the full story here.
Pfizer Completes Acquisition of Trillium Therapeutics
Pfizer Completes Acquisition of Trillium Therapeutics On November 17, 2021, Pfizer Inc. announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. This is a great development for Trillium’s foundational technology, based on innovations originating from the lab of Dr. Jayne Danska The Hospital for Sick Children and collaborators at University Health Network. The novel molecule (TTI-621) targets CD47, augmenting the immune system’s ability to destroy cancer stem cells, by overcoming a "don't eat me" signal. Read the full story here. [...]
SickKids scientist Dr. Jean-Philippe Julien named one of Canada’s Top 40 Under 40
SickKids scientist Dr. Jean-Philippe Julien named one of Canada's Top 40 Under 40 Congratulations to Dr. Jean-Philippe Julien, one of our entrepreneurial scientists at The Hospital for Sick Children, on being named a 2021 Honouree of Canada’s Top 40 Under 40! Read the full story on SickKids.
SickKids and U of T spinout PhenoTips raises $2.5 million in seed funding
SickKids and U of T spinout PhenoTips raises $2.5 million in seed funding Genetics software start-up PhenoTips, a spinout from The Hospital for Sick Children (SickKids) and University of Toronto (U of T), announced this week that it has raised $2.5 million in a seed funding round led by the GreenSky Accelerator Fund IV. The round includes the support of the Toronto Innovation Acceleration Partners, Thin Air Labs, Yorkville Partners, and angel investors including members of the GreenSky President’s Club. Phenotips, previously known as Gene42, began as a joint research project [...]